Treatment of Systemic Mastocytosis With Tamoxifen

Type of Study:

Observational

Study Design:

Observational Model: Case-Only, Time Perspective: Prospective

Outcome Measure:

Stability or reduction of the percent bone marrow involvement by mastocytosis, including stable mast cell morphology and phenotype.

Outcome Description:

up to 40% bone marrow infiltration by mast cells and/or 2) mediator-release symptoms which are not controlled by tolerated doses of standard "non-cytotoxic" medications regardless of the percentage bone marrow involvement by mastocytosis. The dose of Tamoxifen will be 20 mg/day and the duration of treatment will be for one year.

Outcome Time Frame:

1 year

Safety Issue:

No

Principal Investigator

Joseph H Butterfield, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Mayo Clinic

Authority:

United States: Institutional Review Board

Study ID:

2506-04

NCT ID:

NCT01334996

Start Date:

February 2005

Completion Date:

December 2013

Related Keywords:

• Systemic Mastocytosis
• Mastocytosis
• Urticaria Pigmentosa
• Mastocytoma
• Mastocytosis, Systemic

Name	Location
Mayo Clinic	Rochester, Minnesota  55905